Scancell Acquires Neuphoria in All-Share Merger, Plans Nasdaq Listing Under SCLT
The merged company will list on Nasdaq as SCLT and raise up to $89M to fund Phase 3 of its melanoma immunotherapy iSCIB1+.
/ 3 items
#NEUP↓
Neuphoria Explores Sale Options After Drug Trial Failure
Neuphoria Therapeutics initiates strategic review following failed clinical trial. Lynx1 Fund offers $5.20/share buyout as biotech company explores merger and partnership options.
Neuphoria's Social Anxiety Treatment Fails Phase 3 Trial
Neuphoria's AFFIRM-1 Phase 3 trial for BNC210 social anxiety treatment misses all endpoints. Company halts SAD program, reviews options.